CY1125041T1 - Αντισωματα anti-il-22r - Google Patents
Αντισωματα anti-il-22rInfo
- Publication number
- CY1125041T1 CY1125041T1 CY20221100099T CY221100099T CY1125041T1 CY 1125041 T1 CY1125041 T1 CY 1125041T1 CY 20221100099 T CY20221100099 T CY 20221100099T CY 221100099 T CY221100099 T CY 221100099T CY 1125041 T1 CY1125041 T1 CY 1125041T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- relates
- binding fragments
- antigen
- bind
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με αντισώματα και θραύσματα δέσμευσης αντιγόνου αυτών τα οποία συνδέονται με τον υποδοχέα κυτοκίνης IL-22R, ιδιαίτερα τον ανθρώπινο IL-22R. Η εφεύρεση σχετίζεται επίσης με φαρμακευτικές συνθέσεις, οι οποίες περιλαμβάνουν τα εν λόγω αντισώματα ή θραύσματα δέσμευσης αντιγόνου αυτών, και μεθόδους θεραπείας της ψωρίασης, της ψωριασικής αρθρίτιδας ή της ατοπικής δερματίτιδας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1612337.4A GB201612337D0 (en) | 2016-07-15 | 2016-07-15 | Ant-il-22r antibodies |
PCT/EP2017/067923 WO2018011420A1 (en) | 2016-07-15 | 2017-07-14 | Anti-il-22r antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1125041T1 true CY1125041T1 (el) | 2023-03-24 |
Family
ID=56890507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100099T CY1125041T1 (el) | 2016-07-15 | 2022-02-04 | Αντισωματα anti-il-22r |
Country Status (27)
Country | Link |
---|---|
US (4) | US10696741B2 (el) |
EP (2) | EP4023674A3 (el) |
JP (1) | JP7163275B2 (el) |
KR (2) | KR20230128137A (el) |
CN (1) | CN109641966B (el) |
AU (1) | AU2017296094B2 (el) |
BR (1) | BR112019000788A2 (el) |
CA (1) | CA3024370A1 (el) |
CY (1) | CY1125041T1 (el) |
DK (1) | DK3484921T3 (el) |
ES (1) | ES2903412T3 (el) |
GB (1) | GB201612337D0 (el) |
HR (1) | HRP20220197T1 (el) |
HU (1) | HUE057615T2 (el) |
IL (1) | IL264262A (el) |
LT (1) | LT3484921T (el) |
MX (1) | MX2019000539A (el) |
MY (1) | MY197821A (el) |
PL (1) | PL3484921T3 (el) |
PT (1) | PT3484921T (el) |
RS (1) | RS62884B1 (el) |
RU (1) | RU2758721C2 (el) |
SA (1) | SA519400856B1 (el) |
SG (1) | SG11201900128XA (el) |
SI (1) | SI3484921T1 (el) |
UA (1) | UA125585C2 (el) |
WO (1) | WO2018011420A1 (el) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
KR20210019464A (ko) * | 2018-06-05 | 2021-02-22 | 바이오아트라, 인코퍼레이티드 | 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도 |
CN110302363B (zh) * | 2019-07-04 | 2020-10-09 | 北京大学第三医院(北京大学第三临床医学院) | Il-22作为制备治疗pcos药物的应用及药物制剂 |
WO2023232789A1 (en) | 2022-06-03 | 2023-12-07 | Leo Pharma A/S | Liquid formulation of il-22r antibody |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
ATE475673T1 (de) * | 2003-03-24 | 2010-08-15 | Zymogenetics Inc | Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung |
ATE474856T1 (de) * | 2004-10-22 | 2010-08-15 | Zymogenetics Inc | Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen |
WO2007126439A2 (en) * | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
UA105405C2 (ru) * | 2009-11-19 | 2014-05-12 | Мерк Сероно С.А. | Гуманизированное антитело против человеческого il-22ra |
GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
EP2791172B1 (en) * | 2011-12-16 | 2017-07-19 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
WO2014033252A1 (en) | 2012-08-31 | 2014-03-06 | arGEN-X BV | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
US10093737B2 (en) * | 2013-03-01 | 2018-10-09 | Albert Einstein College Of Medicine, Inc. | HHLA2 as a novel inhibitor of human immune system and uses thereof |
CN105601739B (zh) * | 2016-02-22 | 2019-01-18 | 王晨辉 | 一种人源化抗白介素22基因工程抗体及其应用 |
GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
-
2016
- 2016-07-15 GB GBGB1612337.4A patent/GB201612337D0/en not_active Ceased
-
2017
- 2017-07-14 EP EP21208038.6A patent/EP4023674A3/en not_active Withdrawn
- 2017-07-14 WO PCT/EP2017/067923 patent/WO2018011420A1/en unknown
- 2017-07-14 CN CN201780053328.1A patent/CN109641966B/zh active Active
- 2017-07-14 SG SG11201900128XA patent/SG11201900128XA/en unknown
- 2017-07-14 JP JP2019501641A patent/JP7163275B2/ja active Active
- 2017-07-14 CA CA3024370A patent/CA3024370A1/en active Pending
- 2017-07-14 AU AU2017296094A patent/AU2017296094B2/en active Active
- 2017-07-14 SI SI201731037T patent/SI3484921T1/sl unknown
- 2017-07-14 HR HRP20220197TT patent/HRP20220197T1/hr unknown
- 2017-07-14 DK DK17746011.0T patent/DK3484921T3/da active
- 2017-07-14 HU HUE17746011A patent/HUE057615T2/hu unknown
- 2017-07-14 RU RU2019103991A patent/RU2758721C2/ru active
- 2017-07-14 KR KR1020237028376A patent/KR20230128137A/ko active Application Filing
- 2017-07-14 LT LTEPPCT/EP2017/067923T patent/LT3484921T/lt unknown
- 2017-07-14 KR KR1020197001500A patent/KR102571012B1/ko active IP Right Grant
- 2017-07-14 PT PT177460110T patent/PT3484921T/pt unknown
- 2017-07-14 UA UAA201901458A patent/UA125585C2/uk unknown
- 2017-07-14 PL PL17746011T patent/PL3484921T3/pl unknown
- 2017-07-14 EP EP17746011.0A patent/EP3484921B1/en active Active
- 2017-07-14 RS RS20220105A patent/RS62884B1/sr unknown
- 2017-07-14 MX MX2019000539A patent/MX2019000539A/es unknown
- 2017-07-14 BR BR112019000788A patent/BR112019000788A2/pt unknown
- 2017-07-14 MY MYPI2018002752A patent/MY197821A/en unknown
- 2017-07-14 ES ES17746011T patent/ES2903412T3/es active Active
-
2019
- 2019-01-08 US US16/242,760 patent/US10696741B2/en active Active
- 2019-01-10 SA SA519400856A patent/SA519400856B1/ar unknown
- 2019-01-15 IL IL264262A patent/IL264262A/en unknown
- 2019-10-23 US US16/661,783 patent/US11447544B2/en active Active
- 2019-10-23 US US16/661,757 patent/US11261246B2/en active Active
-
2022
- 2022-02-04 CY CY20221100099T patent/CY1125041T1/el unknown
- 2022-08-11 US US17/819,161 patent/US20230088269A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123925T1 (el) | Μια νεα μορφη il33, μεταλλαγμενες μορφες της il33, αντισωματα, δοκιμασιες και μεθοδοι χρησης των ιδιων | |
CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
CY1125041T1 (el) | Αντισωματα anti-il-22r | |
CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
CY1124756T1 (el) | Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας | |
CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
CY1124787T1 (el) | Αντισωματα anti-gitr και μεθοδοι χρησης αυτων | |
CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
CY1123941T1 (el) | Αντι-tfr αντισωματα και χρηση τους στη θεραπεια πολλαπλασιαστικων και φλεγμονωδων διαταραχων | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
CY1125102T1 (el) | Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης | |
CY1124360T1 (el) | Αντισωματα aντι-il-33 και χρησεις αυτων | |
ECSP19086810A (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
MX2018013038A (es) | Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos. | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
ZA201807920B (en) | Anti¿gitr antibodies and uses thereof | |
BR112018002451A2 (pt) | estruturas de ligação com antígeno para moléculas alvo | |
CY1123781T1 (el) | Anti-tnf αλφα-αντισωματα και λειτουργικα θραυσματα αυτων | |
CY1123784T1 (el) | Αντισωματα enanti-tnf αλφα και λειτουργικα θραυσματα αυτων |